Phase 1 N=23 RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
Covid19
Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Parkinson Disease · REM Sleep Behavior Disorder · Healthy
Primary: Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR Imaging — 379.5896; 314.1832; 561.1894; 288.1832 ppb — p=0.66
Phase 3 N=329 Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
Gastroenteritis
Primary: Immune Response to the Licensed Pediatric DTaP-Hib-IPV-HepB Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the…
Phase 1 N=40 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
Migraine
Primary: Number of Participants With Treatment-Emergent Adverse Events — 7; 8; 6; 8 Participants
N/A N=81 Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens
Refractive Error - Myopia Bilateral
Primary: Change From Baseline to Each Post-Baseline Visit in Distance logMAR Visual Acuity (Letters Read) by Eye — 0.3; 0.0; 0.4; 0.4 letters read
N/A N=154 The ADAPT-study: Measuring Physical Performance Using Wearable Sensors in Parkinson's Disease and COPD (ADAPT)
Parkinson Disease · COPD
Primary: Mean Difference in Distance Walked During 6MWT — 33; 15 meter
N/A N=265 A Prospective, Single-Arm Multi-Center Study of the HARMONIC® 1100 Shears in Select Devices
Pediatric Procedures · Adult Hepato-pancreato-biliary (HPB) Procedures · Adult Lower Gastrointestinal Procedures
Primary: Number of Vessels Transected With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale — 484 Vessels transected
Phase 2 N=20 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: Detection and Staging of Head and Neck Squamous Cell Carcinoma Using Standard Uptake Value for NETSPOT Imaging — 7.21; 4.84; 2.87; 2.46 (SUV) volume (cm3)
N/A N=241 Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
Obesity
Primary: Percentage Change of Weight From Baseline — -2.46; -1.97 Percentage change from baseline
N/A N=56 A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
Social Anxiety Disorder (SAD)
Primary: Measurement of Intervention Credibility Assessed With the Credibility Score, at Baseline — 18; 15.4 units on a scale — p=0.1134
Phase 3 N=19 A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
Migraine Disorders
Primary: Assessment of Recruitment Rate — 1.1; 0.6 participants per month
Phase 2 N=181 Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Graft vs. Host Disease
Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008
Phase 2 N=8 Ultrasonic Deep Brain Stimulation During Anesthetic Sedation
Mental Function
Primary: Blood Oxygen Level Dependent (BOLD) Response to Visual Stimuli — 0.56; 0.51 percentage of BOLD signal — p=0.62
N/A N=18 Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Phase 2 N=241 Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Brain Infarct
Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants